JP6137703B2 - 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング - Google Patents

癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング Download PDF

Info

Publication number
JP6137703B2
JP6137703B2 JP2014557953A JP2014557953A JP6137703B2 JP 6137703 B2 JP6137703 B2 JP 6137703B2 JP 2014557953 A JP2014557953 A JP 2014557953A JP 2014557953 A JP2014557953 A JP 2014557953A JP 6137703 B2 JP6137703 B2 JP 6137703B2
Authority
JP
Japan
Prior art keywords
compound
compounds
mark
histone
reprogramming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014557953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515448A (ja
Inventor
ジェイ・エム ジョーンズ、スティーブン
ジェイ・エム ジョーンズ、スティーブン
ヤコヴェンコ、オレクサンドル
タイニー、シルヴィア
チェウン、ピエール、ユルミン
アン、ジアンホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Original Assignee
British Columbia Cancer Agency BCCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA filed Critical British Columbia Cancer Agency BCCA
Publication of JP2015515448A publication Critical patent/JP2015515448A/ja
Application granted granted Critical
Publication of JP6137703B2 publication Critical patent/JP6137703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computing Systems (AREA)
  • Library & Information Science (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014557953A 2012-02-27 2013-02-27 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング Expired - Fee Related JP6137703B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261603650P 2012-02-27 2012-02-27
US61/603,650 2012-02-27
US201261637282P 2012-04-24 2012-04-24
US61/637,282 2012-04-24
PCT/CA2013/050145 WO2013127011A1 (en) 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer

Publications (2)

Publication Number Publication Date
JP2015515448A JP2015515448A (ja) 2015-05-28
JP6137703B2 true JP6137703B2 (ja) 2017-05-31

Family

ID=49081499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557953A Expired - Fee Related JP6137703B2 (ja) 2012-02-27 2013-02-27 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング

Country Status (11)

Country Link
US (1) US9552457B2 (OSRAM)
EP (1) EP2819662B1 (OSRAM)
JP (1) JP6137703B2 (OSRAM)
KR (1) KR102149860B1 (OSRAM)
CN (1) CN104136020B (OSRAM)
AU (1) AU2013225592B2 (OSRAM)
BR (1) BR112014021201B1 (OSRAM)
CA (1) CA2865675C (OSRAM)
IN (1) IN2014DN07812A (OSRAM)
RU (1) RU2637441C2 (OSRAM)
WO (1) WO2013127011A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233198B2 (en) * 2013-03-15 2019-06-27 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
AU2014316783A1 (en) * 2013-09-09 2016-04-28 Glionova Ab Compounds and use for treating cancer
EP3064205A1 (en) * 2015-03-06 2016-09-07 Glionova AB Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
EP3271485A4 (en) * 2015-03-18 2019-01-16 Memorial Sloan-Kettering Cancer Center METHOD FOR DIAGNOSIS AND TREATMENT OF FOLLICULAR LYMPHOMA
JP6862418B2 (ja) 2015-07-31 2021-04-21 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング センサ、カートリッジ、および薬物送達デバイス
JP2021501198A (ja) * 2017-10-27 2021-01-14 トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法
US20230395185A1 (en) * 2020-10-14 2023-12-07 The Regents Of The University Of California Systems for and methods of determining protein-protein interaction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263904A (OSRAM) * 1960-04-26
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3622580A (en) * 1969-03-25 1971-11-23 Smith Kline French Lab Piperazino-acetylamino-9-fluorenones and-anthraquinones
LU85246A1 (fr) * 1984-03-13 1985-10-14 R L Galephar Sa 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
WO2000011206A1 (en) * 1998-08-25 2000-03-02 The Scripps Research Institute Methods and systems for predicting protein function
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
JP5682051B2 (ja) * 2006-05-18 2015-03-11 ファーマサイクリックス，インク． 細胞内キナーゼ阻害剤
WO2009015283A2 (en) * 2007-07-24 2009-01-29 President And Fellows Of Harvard College Bhc80 - histone complexes and uses thereof
CN102369204A (zh) 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
WO2010045199A2 (en) * 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
GB0822248D0 (en) * 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
WO2011014825A2 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
EP2677865A4 (en) 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
WO2012123119A1 (en) 2011-03-17 2012-09-20 Cellzome Ag Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins
WO2013059944A1 (en) 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof

Also Published As

Publication number Publication date
BR112014021201B1 (pt) 2023-01-24
WO2013127011A1 (en) 2013-09-06
US20150154345A1 (en) 2015-06-04
US9552457B2 (en) 2017-01-24
AU2013225592B2 (en) 2017-11-09
EP2819662A1 (en) 2015-01-07
KR102149860B1 (ko) 2020-08-31
CA2865675A1 (en) 2013-09-06
AU2013225592A2 (en) 2014-10-09
CN104136020B (zh) 2018-08-28
RU2637441C2 (ru) 2017-12-04
AU2013225592A1 (en) 2014-10-09
JP2015515448A (ja) 2015-05-28
BR112014021201A2 (pt) 2021-06-08
EP2819662A4 (en) 2016-03-23
CN104136020A (zh) 2014-11-05
CA2865675C (en) 2023-02-28
RU2014138543A (ru) 2016-04-20
EP2819662B1 (en) 2019-04-10
KR20140132382A (ko) 2014-11-17
IN2014DN07812A (OSRAM) 2015-05-15

Similar Documents

Publication Publication Date Title
JP6137703B2 (ja) 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング
TW201728583A (zh) 氨基噻唑化合物及其用途
EP2909194A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9446039B2 (en) Aminoheteroaryl compounds as MTH1 inhibitors
CN101801401A (zh) 激酶蛋白质结合抑制剂
AU2017221422A1 (en) MAX binders as Myc modulators and uses thereof
US20250263404A1 (en) Aminopyridines as activators of pi3 kinase
CN110214010A (zh) 组合疗法
JP6483804B2 (ja) 新規なｈｄｍｘ阻害剤およびガン治療のためのその使用
CN107949279A (zh) 可用作用于治疗人类癌症的抗癌剂的苯甲酰胺或苯扎明化合物
Wang et al. Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo
KR102285119B1 (ko) 신규한 히스톤 메틸 트랜스퍼라아제 억제제 및 그 용도
WO2024167565A1 (en) Ptp1b/tc-ptp dual inhibitors and protein degraders
Namdeo et al. Synthesis and bio evaluation of some hybrid molecules of tramadol: A new strategy in drug design
Liu et al. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-N-arylacetamides as novel HSP90 C-terminal inhibitors
EP4552695A2 (en) Tyrosine kinases inhibitors and uses thereof
US20180335421A1 (en) Method for screening inhibitors targeting anti-apoptotic survival pathways
US20220306603A1 (en) Targeting dna repair in tumor cells via inhibition of ercc1-xpf
Chen et al. Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor. Front
Abdelsalam Development and biological characterization of novel class I histone deacetylases modulators
Singh et al. A review on Carbonic Anhydrase IX and XII Inhibitors
TW202523322A (zh) 吉西他濱抗癌衍生物及其抗癌醫藥用途和製備方法
Liu et al. Identification of a Novel and Potent Oxadiazole-Based Sphingosine Kinase 2 Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of Prostatic Cancer
KR20110128911A (ko) 키나아제 단백질 결합 억제제
HK1147417A (en) Kinase protein binding inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170323

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170421

R150 Certificate of patent or registration of utility model

Ref document number: 6137703

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees